Reduction of the pro-inflammatory response by tetrandrine-loading poly(L-lactic acid) films in vitro and in vivo

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 11, 2014, Pages 4098-4107

  Wang, Qiang Song ^a,b   Cui, Yuan Lu ^b   Gao, Li Na ^b   Guo, Yong ^a   Li, Rui Xin ^a   Zhang, Xi Zheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anti inflammatory; Foreign body response; Macrophage; Poly(L lactic acid); Tetrandrine

Indexed keywords

AUTOMOBILE BODIES; BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; CHEMICAL ANALYSIS; DRUG DELIVERY; ELECTRON SPECTROSCOPY; MACROPHAGES; NEURAL PROSTHESES; SALICYLIC ACID;

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY EFFECTS; DRUG DELIVERY VEHICLES; ELECTRON SPECTROSCOPY FOR CHEMICAL ANALYSIS; FOREIGN BODY RESPONSE; POLY L LACTIC ACID; TETRANDRINE; WATER CONTACT ANGLE MEASUREMENT;

LACTIC ACID;

BIOMATERIAL; CHEMOKINE; CYTOKINE; ENZYME; INTERLEUKIN 6; NITRIC OXIDE; NITROGEN; POLYLACTIC ACID; SALICYLIC ACID; TETRANDRINE; TUMOR NECROSIS FACTOR ALPHA; WATER; ARTIFICIAL MEMBRANE; AUTACOID; BENZYLISOQUINOLINE DERIVATIVE; DELAYED RELEASE FORMULATION; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; POLYMER;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CHEMICAL ANALYSIS; CONTACT ANGLE; DRUG DELIVERY SYSTEM; FOREIGN BODY; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; RAT; SPECTROSCOPY; SUBURETHRAL SLING; TISSUE ENGINEERING; ANIMAL; ARTIFICIAL MEMBRANE; CELL LINE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; MALE; METABOLISM; MOUSE; PHARMACOLOGY; WISTAR RAT;

ANIMALS; BENZYLISOQUINOLINES; CELL LINE; DELAYED-ACTION PREPARATIONS; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; LACTIC ACID; MALE; MEMBRANES, ARTIFICIAL; MICE; POLYMERS; RATS; RATS, WISTAR; SALICYLIC ACID;

EID: 84908076368     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35083     Document Type: Article

References (60)

1. Liu WG, Li XW, Li YS, Cai KY, Yao KD, Yang Z, Li X. Effects of baicalin-modified poly(D,L-lactic acid) surface on the behavior of osteoblasts. J Mater Sci Mater Med 2003;14:961-965.
2. Rizzi SC, Heath DJ, Coombes AG, Bock N, Textor M, Downes S. Biodegradable polymer/hydroxyapatite composites: surface analysis and initial attachment of human osteoblasts. J Biomed Mater Res 2001;55:475-486.
3. Ge Z, Yang F, Goh JC, Ramakrishna S, Lee EH. Biomaterials and scaffolds for ligament tissue engineering. J Biomed Mater Res A 2006;77:639-652.
4. Cosgriff-Hernandez E, Mikos AG. New biomaterials as scaffolds for tissue engineering. Pharm Res 2008;25:2345-2347.
5. Yoon H, Ahn S, Kim G. Three-dimensional polycaprolactone hierarchical scaffolds supplemented with natural biomaterials to enhance mesenchymal stem cell proliferation. Macromol Rapid Commun 2009;30:1632-1637.
6. Seras-Franzoso J, Steurer C, Roldan M, Vendrell M, Vidaurre-Agut C, Tarruella A, Saldana L, Vilaboa N, Parera M, Elizondo E, Ratera I, Ventosa N, Veciana J, Campillo-Fernandez AJ, Garcia-Fruitos E, Vazquez E, Villaverde A. Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. J Control Release 2013;171:63-72.
7. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007;117:68-79.
8. Kose GT, Korkusuz F, Korkusuz P, Hasirci V. In vivo tissue engineering of bone using poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid) and collagen scaffolds. Tissue Eng 2004;10:1234-1250.
9. Klueh U, Dorsky DI, Moussy F, Kreutzer DL. Ex ova chick chorioallantoic membrane as a novel model for evaluation of tissue responses to biomaterials and implants. J Biomed Mater Res A 2003;67:838-843.
10. Sennerby L, Thomsen P, Ericson LE. Early tissue response to titanium implants inserted in rabbit cortical bone. J Mater Sci: Mater Med 1993;4:494-502.
11. McNally AK, Anderson JM. Macrophage fusion and multinucleated giant cells of inflammation. Adv Exp Med Biol 2011; 713:97-111.
12. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002;111:927-930.
13. Anderson JM, Miller KM. Biomaterial biocompatibility and the macrophage. Biomaterials 1984;5:5-10.
14. Schnyder J, Baggiolini M. Role of phagocytosis in the activation of macrophages. J Exp Med 1978;148:1449-1457.
15. Salthouse TN. Some aspects of macrophage behavior at the implant interface. J Biomed Mater Res 1984;18:395-401.
16. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-686.
17. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009;27:451-483.
18. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
19. Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996;97:1837-1843.
20. Wang QS, Cui YL, Dong TJ, Zhang XF, Lin KM. Ethanol extract from a Chinese herbal formula, "Zuojin Pill", inhibit the expression of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 mouse macrophages. J Ethnopharmacol 2012;141:377-385.
21. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-12234.
22. Ferret PJ, Soum E, Negre O, Fradelizi D. Auto-protective redox buffering systems in stimulated macrophages. BMC Immunol 2002;3:3.
23. Wang QS, Cui YL, Wang YF, Chi W. Effects of compounds from bi-qi capsule on the expression of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Ethnopharmacol 2011;136:480-487.
24. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-266.
25. Pan MH, Lai CS, Wang YJ, Ho CT. Acacetin suppressed LPSinduced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice. Biochem Pharmacol 2006;72:1293-1303.
26. Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, Lee KT. Antiinflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-kappaB inactivation. Br J Pharmacol 2006;148:216-225.
27. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-150.
28. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
29. Koo HJ, Song YS, Kim HJ, Lee YH, Hong SM, Kim SJ, Kim BC, Jin C, Lim CJ, Park EH. Antiinflammatory effects of genipin, an active principle of gardenia. Eur J Pharmacol 2004;495:201-208.
30. Li WJ, Cooper JA, Jr, Mauck RL, Tuan RS. Fabrication and characterization of six electrospun poly(alpha-hydroxy ester)-based fibrous scaffolds for tissue engineering applications. Acta Biomater 2006;2:377-385.
31. Cui YL, Qi AD, Liu WG, Wang XH, Wang H, Ma DM, Yao KD. Biomimetic surface modification of poly(L-lactic acid) with chitosan and its effects on articular chondrocytes in vitro. Biomaterials 2003;24:3859-3868.
32. Lin ST, Wang Y, Xue Y, Feng DC, Xu Y, Xu LY. Tetrandrine suppresses LPS-induced astrocyte activation via modulating IKKs- IkappaBalpha-NF-kappaB signaling pathway. Mol Cell Biochem 2008;315:41-49.
33. Gao S, Cui YL, Yu CQ, Wang QS, Zhang Y. Tetrandrine exerts antidepressant-like effects in animal models: Role of brainderived neurotrophic factor. Behav Brain Res 2013;238:79-85.
34. Lai JH. Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases. Acta Pharmacol Sin 2002;23:1093-1101.
35. Kim HS, Zhang YH, Oh KW, Ahn HY. Vasodilating and hypotensive effects of fangchinoline and tetrandrine on the rat aorta and the stroke-prone spontaneously hypertensive rat. J Ethnopharmacol 1997;58:117-123.
36. Chen Y, Chen JC, Tseng SH. Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 2009; 124:2260-2269.
37. Wang G, Lemos JR. Tetrandrine: A new ligand to block voltagedependent Ca21 and Ca(1)-activated K1 channels. Life Sci 1995; 56:295-306.
38. Sun F, Liu TP. Tetrandrine vs nicardipine in cerebral ischemiareperfusion damages in gerbils. Zhongguo Yao Li Xue Bao 1995; 16:145-148.
39. Yu XF, Zou CQ, Lin MB. Observation of the effect of tetrandrine on experimental silicosis of rats. Ecotoxicol Environ Saf 1983;7: 306-312.
40. Wang QS, Xiang Y, Cui YL, Lin KM, Zhang XF. Dietary blue pigments derived from genipin, attenuate inflammation by inhibiting LPS-induced iNOS and COX-2 expression via the NF-kappaB inactivation. PLoS One 2012;7:e34122.
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
42. Navarro M, Michiardi A, Castaño O, Planell PA. Biomaterials in orthopaedics. J R Soc Interface 2008;5:1137-1158.
43. Yang F, Murugan R, Ramakrishna S, Wang X, Ma YX, Wang S. Fabrication of nano-structured porous PLLA scaffold intended for nerve tissue engineering. Biomaterials 2004;25:1891-1900.
44. Chen JP, Su CH. Surface modification of electrospun PLLA nanofibers by plasma treatment and cationized gelatin immobilization for cartilage tissue engineering. Acta Biomater 2011;7:234-243.
45. Kim KL, Han DK, Park K, Song SH, Kim JY, Kim JM, Ki HY, Yie SW, Roh CR, Jeon ES, et al. Enhanced dermal wound neovascularization by targeted delivery of endothelial progenitor cells using an RGD-g-PLLA scaffold. Biomaterials 2009;30:3742-3748.
46. Niu X, Feng Q, Wang M, Guo X, Zheng Q. Porous nano-HA/collagen/ PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. J Control Release 2009;134:111-117.
47. Takebe J, Champagne CM, Offenbacher S, Ishibashi K, Cooper LF. Titanium surface topography alters cell shape and modulates bone morphogenetic protein 2 expression in the J774A.1 macrophage cell line. J Biomed Mater Res A 2003;64:207-216.
48. Tsirogianni AK, Moutsopoulos NM, Moutsopoulos HM. Wound healing: Immunological aspects. Injury 2006;37 (Suppl 1):S5-S12.
49. Saino E, Focarete ML, Gualandi C, Emanuele E, Cornaglia AI, Imbriani M, Visai L. Effect of electrospun fiber diameter and alignment on macrophage activation and secretion of proinflammatory cytokines and chemokines. Biomacromolecules 2011;12:1900-1911.
50. Bartneck M, Schulte VA, Paul NE, Diez M, Lensen MC, Zwadlo-Klarwasser G. Induction of specific macrophage subtypes by defined micro-patterned structures. Acta Biomater 2010;6:3864-3872.
51. Chen S, Jones JA, Xu Y, Low HY, Anderson JM, Leong KW. Characterization of topographical effects on macrophage behavior in a foreign body response model. Biomaterials 2010;31:3479-3491.
52. Tan KS, Qian L, Rosado R, Flood PM, Cooper LF. The role of titanium surface topography on J774A.1 macrophage inflammatory cytokines and nitric oxide production. Biomaterials 2006;27:5170-5177.
53. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005;4:471-479.
54. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
55. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-3232.
56. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013-12017.
57. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-142.
58. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
59. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-896.
60. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11:613-624.